Endomeda, UAB - financials and debts

Company age: 28 y. 6 mo.

Update

Endomeda - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 519,746 408,670 503,105 489,864 437,485 494,390 507,914 439,721
Profit before tax 115,249 73,717 171,288 130,334 88,051 128,704 119,151 69,183
Net profit 98,113 61,522 145,547 110,549 81,499 109,662 101,652 57,824
Equity 423,603 325,125 470,672 581,221 462,720 572,382 674,034 731,858
Liabilities 103,653 24,738 58,641 42,897 27,614 174,496 157,229 42,493
Non-current assets 148,465 126,107 107,712 90,937 123,991 98,698 76,856 55,707
Current assets 378,791 223,756 421,537 539,932 373,169 654,399 753,737 717,973
Total assets 527,256 349,863 529,249 630,869 497,160 753,097 830,593 773,680
Taxes paid
STI taxes - - - - - 35,792 31,002 61,249
Social insurance contributions - - - - - 12,546 12,744 13,322
Financial indicators
Revenue change y/y +26.9% -21.4% +23.1% -2.6% -10.7% +13.0% +2.7% -13.4%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 18.6% 17.6% 27.5% 17.5% 16.4% 14.6% 12.2% 7.5%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 23.2% 18.9% 30.9% 19.0% 17.6% 19.2% 15.1% 7.9%
Profit margin Net profit margin. Shows the overall profitability of the company. 18.9% 15.1% 28.9% 22.6% 18.6% 22.2% 20.0% 13.2%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 22.2% 18.0% 34.0% 26.6% 20.1% 26.0% 23.5% 15.7%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.2 0.1 0.1 0.1 0.1 0.3 0.2 0.1
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 68,538 51,084 62,888 69,158 72,914 83,558 84,652 85,107

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Endomeda - Social security debts

From To Debt, €
2025-09-16 2025-09-16 196.51
2025-08-31 2025-09-02 119.37
2025-08-19 2025-08-29 119.37
2025-07-16 2025-07-31 53.42

Endomeda - VMI tax arrears

From To Overdue, €
2026-01-20 2026-01-23 165.25
2026-01-16 2026-01-19 164.21
2025-11-20 2025-11-25 8.15
2025-06-19 2025-06-19 0.15
2025-05-29 2025-06-16 0.15
2025-04-28 2025-05-13 0.15
2025-04-04 2025-04-18 0.15
2025-04-03 2025-04-03 160.41
2025-03-28 2025-04-02 0.15
2025-03-20 2025-03-24 1.77
2025-02-28 2025-03-15 1.77
2025-02-19 2025-02-24 1.7
2025-02-18 2025-02-18 2.7
2025-02-12 2025-02-17 0.72
2025-02-04 2025-02-11 655.73
2025-02-02 2025-02-03 660.93
2025-01-31 2025-02-01 656.07
2025-01-30 2025-01-30 655.01
2025-01-17 2025-01-24 655.01

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Endomeda, UAB (code 135128174) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In financial year 2025, the company generated revenue of €439.7K and net profit of €57.8K, resulting in a profit margin of 13.2%. Performance weakened year on year, with revenue down 13.4% from 2024 and also below the 2023 level. Profit followed the same direction, falling from €109.7K in 2023 to €101.7K in 2024 and €57.8K in 2025. The balance sheet remained conservative, with total assets of €773.7K, equity of €731.9K and liabilities of €42.5K at the end of 2025. This corresponds to an equity ratio of 94.6% and a debt-to-equity ratio of 0.06. Asset turnover was 0.57x, while return on equity was 7.9% and return on assets 7.5%. Productivity indicators show revenue per employee of €87.9K and profit per employee of €11.6K.